NCT07813663
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Recruitment opened
- Enrollment increased: 188 → 212 participants
- Study sites: 0 to 2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants Reporting Treatment-emergent Adverse Events
Timeframe: Day 1 of dosing and monitoring period up to 7 days after last dose (Safety Follow Up Visit)
Pharmacokinetic Parameter Maximum Concentration (Cmax) of JZP269
Timeframe: Predose up to 48 hours postdose
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) of JZP269
Timeframe: Predose up to 48 hours postdose
Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP269
Timeframe: Predose up to 48 hours postdose
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP269
Timeframe: Predose up to 48 hours postdose
Pharmacokinetic Parameter Oral Clearance (CL/F) of JZP269
Timeframe: Predose up to 48 hours postdose
Pharmacokinetic Parameter Apparent Volume of Distribution During the Terminal Phase (Vz/F) of JZP269
Timeframe: Predose up to 48 hours postdose
Secondary (9)
Dose Proportionality of JZP269 Area Under the Concentration-Time Curve (AUC)
Dose Proportionality of JZP269 Maximum Concentration (Cmax)
The Effect of Food on the PK of JZP269 Cmax
The Effect of Food on the PK of JZP269 Tmax
The Effect of Food on the PK of JZP269 t1/2
Show 4 moreShow less
The Effect of Food on the PK of JZP269 AUC
Mean Concentrations of JZP269 in Cerebrospinal Fluid
Mean Sleep Latency on the Maintenance of Wakefulness Test (MWT) in Sleep-deprived Participants
Mean Karolinska Sleepiness Scale (KSS) Score in Sleep-deprived Participants
Arms and interventions
JZP269Experimental
Participants will receive JZP269.
PlaceboPlacebo comparator
Participants will receive a matching placebo.
Drugs: JZP269, Placebo
Sites
2 sites in 1 country